Showing results (321-330 of 398) with videos related to
Sort By:
Pageof 40
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 15, 2026
Extended Endocrine Therapy Following 5 Years of Adjuvant Luteinizing Hormone-Releasing Hormone Agonist in Premenopausal Patients With Node-Positive, Hormone Receptor-Positive Breast Cancer: A Cohort StudyCarmine Valenza, Yue Zheng, Monica Milano, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 21, 2022
Development and Validation of a Predictive Model of Severe Fatigue After Breast Cancer Diagnosis: Toward a Personalized Framework in Survivorship CareAntonio Di Meglio, Julie Havas, Davide Soldato, et al.Journal of the National Cancer Institute|May 5, 2022
Impact of Age on Clinical Outcomes and Efficacy of Adjuvant Dual Anti-HER2 Targeted TherapyMatteo Lambertini, Shona Fielding, Sibylle Loibl, et al.The New England Journal of Medicine|January 8, 2015
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancerSara M Tolaney, William T Barry, Chau T Dang, et al.Breast (Edinburgh, Scotland)|April 29, 2020
Changes in weight, physical and psychosocial patient-reported outcomes among obese women receiving treatment for early-stage breast cancer: A nationwide clinical studyAntonio Di Meglio, Stefan Michiels, Lee W Jones, et al.Breast Cancer Research and Treatment|April 21, 2019
Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial)Jennifer R Bellon, Hao Guo, William T Barry, et al.Breast Cancer Research and Treatment|May 19, 2015
Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial)Kathryn J Ruddy, Hao Guo, William Barry, et al.NPJ Breast Cancer|May 10, 2022
A prospective trial of treatment de-escalation following neoadjuvant paclitaxel/trastuzumab/pertuzumab in HER2-positive breast cancerAdrienne G Waks, Neelam V Desai, Tianyu Li, et al.Journal of the National Cancer Institute|August 1, 2022
Surveillance Imaging vs Symptomatic Recurrence Detection and Survival in Stage II-III Breast Cancer (AFT-01)Jessica R Schumacher, Heather B Neuman, Menggang Yu, et al.Breast Cancer Research and Treatment|November 5, 2020
Response to neoadjuvant chemotherapy and the 21-gene Breast Recurrence Score test in young women with estrogen receptor-positive early breast cancerTal Sella, Shari I Gelber, Philip D Poorvu, et al.Pageof 40